Banner
Banner
Bioscreening Company Directory

Mitsubishi Chemical Corporation

Mitsubishi Chemical Corporation 14-1 Shiba 4-chome, Minato-ku
108-0014 Tokyo Japan
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Website
Mitsubishi Kasei Corporation and Mitsubishi Petrochemical Co., Ltd. merged and started the operation as Mitsubishi Chemical Corporation.
Mitsubishi Kasei Corporation Mitsubishi Kasei Corporation
Mitsubishi Petrochemical Co., Ltd. Mitsubishi Petrochemical Co., Ltd.
Mitsubishi Chemical Corporation Mitsubishi Chemical Corporation
Aug 1934 Mitsubishi Kasei Corporation The predecessor of Mitsubishi Chemical Industries Limited was founded.
Oct 1935 Mitsubishi Kasei Corporation Kurosaki Plant started its operation.
Jun 1950 Mitsubishi Kasei Corporation Mitsubishi Chemical Industries Limited (the predecessor of Mitsubishi Kasei Corporation) was listed on the Tokyo Stock Exchange.
Aug 1950 Mitsubishi Kasei Corporation Osaka Branch Office was established.
Jul 1953 Mitsubishi Kasei Corporation Mitsubishi Chemical Industries Limited (the predecessor of Mitsubishi Kasei Corporation) merged with Toho Kagaku Kogyo (Yokkaichi Plant), and the Plant started its operation as Yokkaichi Plant (present Yokkaichi Plant) of Mitsubishi Chemical Industries Limited.
Apr 1956 Mitsubishi Kasei Corporation Mitsubishi Group and Shell Group jointly established Mitsubishi Petrochemical Co., Ltd.

Mitsubishi Kasei Corporation Mitsubishi Chemical Industries Limited (the predecessor of Mitsubishi Kasei Corporation) established Tokyo Branch Office (- Sep 2000), Nagoya Branch Office (present Chubu Branch Office), and Kyushu Branch Office.
May 1959 Mitsubishi Kasei Corporation Mitsubishi Petrochemical Co., Ltd. started its operation of Yokkaichi Division (present Yokkaichi Plant).
Feb 1961 Mitsubishi Kasei Corporation Duesseldorf Office (present Mitsubishi Chemical Europe GmbH) was established.
Apr 1961 Mitsubishi Kasei Corporation New York Office (present Mitsubishi Chemical America, Inc.) was established.
May 1963 Mitsubishi Kasei Corporation Naoetsu Plant started its operation.
Jul 1964 Mitsubishi Kasei Corporation Mizushima Plant started its operation.
Apr 1968 Mitsubishi Kasei Corporation Tsukuba Research Center (present MCC-Group Science & Technology Office, Tsukuba Center) was established.
Nov 1969 Mitsubishi Kasei Corporation Sakaide Plant started its operation.
Jan 1971 Mitsubishi Kasei Corporation Kashima Division (present Kashima Plant, Tobu Zone) started its operation.
Apr 1971 Mitsubishi Kasei Corporation Hong Kong Office (present Mitsubishi Chemical Hong Kong Ltd.) was established.
Apr 1975 Mitsubishi Kasei Corporation Mitsubishi Kasei Do Brasil Limitada (- 2003) was established.
Feb 1976 Mitsubishi Kasei Corporation Research Center (present MCC-Group Science & Technology Office, Yokohama Center) was established.
May 1978 Mitsubishi Kasei Corporation Kashima Plant (present Kashima Plant, Hasaki Zone) started its operation.
May 1986 Mitsubishi Kasei Corporation Odawara Plant was established.
Dec 1986 Mitsubishi Kasei Corporation Chigasaki Plant (- Dec 1997) was established.
Jun 1988 Mitsubishi Kasei Corporation Mitsubishi Chemical Industries Limited changed the corporate name to Mitsubishi Kasei Corporation.
Oct 1990 Mitsubishi Kasei Corporation Mitsubishi Kasei Corporation merged with Matsuyama Kasei Ltd. (Matsuyama Plant), and the Plant started its operation as Matsuyama Plant of Mitsubishi Kasei Corporation.
Apr 1991 Mitsubishi Kasei Corporation Hiroshima Branch Office (- Oct 1999), and Sapporo Branch Office (present Hokkaido Branch Office) were established.
Oct 1991 Mitsubishi Kasei Corporation Mitsubishi Kasei Corporation merged with the Kasei Naoetsu Industries Limited (Naoetsu Plant) and the Plant started its operation as Naoetsu Plant of Mitsubishi Kasei Corporation.
Apr 1992 Mitsubishi Kasei Corporation Mitsubishi Kasei Singapore Pte Ltd (present Mitsubishi Chemical Singapore Pte Ltd) was established.
Oct 1992 Mitsubishi Kasei Corporation Mitsubishi Kasei Corporation merged with Mitsubishi Kasei Polytec Company (Tsukuba Plant) and JTC, and the Plant started its operation as Tsukuba Plant of Mitsubishi Kasei Corporation.
Jan 1993 Mitsubishi Kasei Corporation Taiwan Branch Office (- Jun 1998) was established.
Apr 1993 Mitsubishi Kasei Corporation Sendai Branch Office (- Oct 1999) was established.
Jul 1993 Mitsubishi Kasei Corporation Beijing Branch Office (present Beijing Office of Mitsubishi Chemical Corporation) was established.
Mar 1994 Mitsubishi Kasei Corporation Mitsubishi Kasei Thailand Co., Ltd. (present Mitsubishi Chemical (Thailand) Co., Ltd.) was established.
Oct 1994 Mitsubishi Kasei Corporation Mitsubishi Kasei Corporation and Mitsubishi Petrochemical Co., Ltd. merged and started the operation as Mitsubishi Chemical Corporation.
Mar 1995 Mitsubishi Kasei Corporation Jakarta Office (- Apr 2000) was established.
Oct 1999 Mitsubishi Kasei Corporation Mitsubishi Chemical Corporation merged with Tokyo Tanabe Co., Ltd. and established a subsidiary, Mitsubishi-Tokyo Pharmaceuticals, Inc., to take over combined pharmaceutical operations.
Oct 2001 Mitsubishi Kasei Corporation Mitsubishi-Tokyo Pharmaceuticals, Inc. and Welfide Corporation merged and started the operation as a subsidiary of Mitsubishi Chemical Corporation, Mitsubishi Pharma Corporation.
Jul 2003 Mitsubishi Kasei Corporation Mitsubishi Chemical Corporation established an independent company, Mitsubishi Chemical Group Science and Technology Research Center, Inc. as a corporate central research.
Oct 2003 Mitsubishi Kasei Corporation Mitsubishi Chemical Corporation relocated the head office to Minato-ku, Tokyo.
Oct 2005 Mitsubishi Kasei Corporation Mitsubishi Chemical Corporation and Mitsubishi Pharma Corporation jointly established a holding company, Mitsubishi Chemical Holdings Corporation, by means of a stock-for-stock exchange.
Oct 2006 Mitsubishi Kasei Corporation MitsubishiChemical Corporation relocated the head office to Shiba 4-chome, Minato-ku, Tokyo.

WaySearch
  
Powered by Sigsiu.NET RSS Feeds
ScienceDaily (May 16, 2012) — Microscopes provide valuable insights in the structure and dynamics of cells, in particular when the latter remain in their natural environment. However, this is very difficult especially for higher organisms. Researchers of Karlsruhe Institute of Technology (KIT), the Max Planck Institute for Polymer Research, Mainz, and the American National Institutes of Health (NIH) have now developed a new method to visualize cell structures of an eighth of a micrometer in size in living fish larvae. Read the Full Story
ScienceDaily (May 15, 2012) — Astrophysicists have just discovered a new heating source in cosmological structure formation. Until now, astrophysicists thought that super-massive black holes could only influence their immediate surroundings. A collaboration of scientists at the Heidelberg Institute for Theoretical Studies (HITS) and in Canada and the US have now discovered that diffuse gas in the universe can absorb luminous gamma-ray emission from black holes, heating it up strongly. This surprising result has important implications for the formation of structures in the universe. Read the Full Story
ScienceDaily (May 15, 2012) — Astrophysicists have just discovered a new heating source in cosmological structure formation. Until now, astrophysicists thought that super-massive black holes could only influence their immediate surroundings. A collaboration of scientists at the Heidelberg Institute for Theoretical Studies (HITS) and in Canada and the US have now discovered that diffuse gas in the universe can absorb luminous gamma-ray emission from black holes, heating it up strongly. This surprising result has important implications for the formation of structures in the universe. Read the Full Story
ScienceDaily (May 13, 2012) — Using tiny solar-panel-like cells surgically placed underneath the retina, scientists at the Stanford University School of Medicine have devised a system that may someday restore sight to people who have lost vision because of certain types of degenerative eye diseases. Read the Full Story
ScienceDaily (May 10, 2012) — A new study published in Science May 11 is shedding light on the molecular details of PARP-1, a DNA damage-detecting enzyme that when inhibited has been shown to be effective in fighting cancer and other diseases. Read the Full Story
ScienceDaily (May 14, 2012) — Prickly pufferfish could hold the key to why humans do not continually replace their teeth and may lead to advances in dental therapies. Read the Full Story
image Microscope Looks Into Cells of Living Fish
image Sulfur Finding May Hold Key to Gaia Theory of Earth as Living Organism
image Black Holes Turn Up the Heat for the Universe
image Tiny Solar-Panel-Like Cells Help Restore Sight to the Blind
image Why Inhibiting DNA Damage-Detecting Enzyme Is Effective in Fighting Cancer and Other Diseases
image Pufferfish at the 'Beak' of Evolution: Why Humans Don't Continuously Replace Their Teeth

BioScreening News

  • Evotec Becomes First European CRO to Offer Agilent’s RapidFire Screening Tool
    Evotec is adding Agilent Technologies’ RapidFire mass spectrometry analysis capabilities to its high-throughput screening facilities in Hamburg. RapidFire is an in-line solid-phase extraction technology. It enables ultrafast, direct analysis of native compounds for a variety of biochemical assays including routine ADME and lead discovery applications across a range of therapeutic...
  • Pfizer’s Torisel Misses Endpoints in Renal Cell Carcinoma Trial Testing Second-Line Setting
    Pfizer’s drug candidate for advanced renal cell carcinoma (RCC), Torisel, failed to meet the primary endpoint of progression-free survival in the Phase III Intorsect study. The trial compared Torisel and Nexavar in patients whose disease had progressed on or after treatment with the company’s approved drug Sutent. Although PFS was...
  • Lonza, Avalanche Partner on Baculovirus-Based AAV Manufacturing Platform
    Biologics manufacturer Lonza and ocular gene therapy specialist Avalanche Biotechnologies established a global manufacturing collaboration to aid in the latter’s gene therapy programs. Avalanche’s lead wet age-related macular degeneration (wet-AMD) gene therapy candidate AVA-101 started in early clinical trials at the end of 2011. The partnership will focus on the...
  • IntelligentMDx Wins CE Mark for Group B Strep Assay on Abbott m2000 Instrument
    IntelligentMDx received a CE Mark for its qualitative Group B Streptococcus (GBS) in vitro diagnostic, IMDx GBS, for use on the Abbott m2000™ system. The assay is used to screen for Group B Streptococcus infection in at-risk pregnant women and women in labor. The real-time PCR test can be carried...
  • Admescope to Provide PlexPress Multiplex CYP Gene Expression Analysis Technology
    CRO Admescope will offer PlexPress’ TRAC (transcript analysis with the aid of affinity capture) platform for high-throughput gene expression analysis as part of its in vitro drug interaction and preclinical ADME-Tox services. Finland-based Admescope will initially offer Plexpress’ multiplex cytochrome P450 (CYP) assays. The firm says the service will meet...
  • Six Suitors Join Bristol-Myers in Considering a Bid for Amylin
    After turning down an unsolicited bid from Bristol-Myers Squibb (BMS) in February, Amylin Pharmaceuticals is preparing to weigh offers from BMS and up to six other potential suitors. Citing unnamed “people familiar with the matter,” Bloomberg News reported that BMS has joined AstraZeneca, Merck & Co., Pfizer, Roche, Sanofi, and...
  • Accelr8, Denver Health Win $2M to Develop Battlefield Infections Diagnostic
    Accelr8 and Denver Health received notification that the Defence Medical Research and Development Program (DMRPD) has recommended a $2 million award to support a three-year project focused on developing a rapid diagnostic system for wound infections and serious infections secondary to trauma. The project was the sole recipient of funds...
  • Gamida Cell Raises $10M to Progress Phase III-Stage Hematologic Cancer Cell Therapy
    Gamida Cell raised $10 million through an internal Series E financing round with all its existing major shareholders. The proceeds will be used to support global commercialization of the firm’s Phase III-stage StemEx cord blood stem cell therapy for blood cancers, and continue development of additional pipeline candidates, including clinical...
  • ALS Institute, Neurotune to Evaluate Amyotrophic Lateral Sclerosis Therapeutic Candidate
    The ALS Therapeutic Institute and Neurotune established a collaboration to evaluate one of the latter’s neuromuscular diseases candidates in an ALS disease model. ALS is associated with motor neurons and their axons becoming disconnected from muscle, and Neurotune has identified a class of compounds designed to maintain neuromuscular junction strength...
  • KineMed, CHDI Ally on Biomarkers of Huntington Disease Progression, Drug Efficacy
    CHDI Foundation and KineMed established a collaboration to exploit the latter’s tandem mass spectrometry-based proteomics platform to analyze the in vivo dynamics of mutant huntingtin protein as a means of assessing Huntington disease progression and measuring the efficacy of therapeutic candidates. The aim is to generate data that will both...

Life Science Events

April 2012 May 2012 June 2012
Su Mo Tu We Th Fr Sa
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31
Recent events
View full calendar
1 DOW 12,575.39
-23.16 (-0.18%)    
2 S&P 1,318.39
-6.41 (-0.48%)    
3 NASDAQ 2,849.48
-24.56 (-0.85%)